Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease

NCT00035880 is registered in ClinicalTrials.gov with Abgenix as lead sponsor.

NCT NCT00035880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00035880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease
Lead sponsor
Abgenix
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 1999
Completion date
June 30, 2003
Enrollment
95
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft vs host disease